Journal profile · ALLERGY-IMMUNOLOGY
Allergy Asthma and Clinical Immunology
ISSN 1710-1484 · eISSN 1710-1492 · BioMed Central · ENGLAND · Founded 2005
Allergy Asthma and Clinical Immunology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.96; fully open access; APC about USD 3,190; median 119 days to acceptance (92 articles, last 24 months); 66 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Allergy Asthma and Clinical Immunology is published by BioMed Central and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Asthma and respiratory diseases, Allergic Rhinitis and Sensitization and Food Allergy and Anaphylaxis Research, together about 43.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Allergy, Asthma & Clinical Immunology (AACI), the official journal of the Canadian Society of Allergy and Clinical Immunology (CSACI), is an open access journal that encompasses all aspects of diagnosis, epidemiology, prevention and treatment of allergic and immunologic disease. By offering a high-visibility forum for new insights and discussions, AACI provides a platform for the dissemination of allergy and clinical immunology research and reviews amongst allergists, pulmonologists, immunologists and other physicians, healthcare workers, medical students and the public worldwide. AACI reports on basic research and clinically applied studies in the following areas and other related topics: asthma and occupational lung disease, rhinoconjunctivitis and rhinosinusitis, drug hypersensitivity, allergic skin diseases, urticaria and angioedema, venom hypersensitivity, anaphylaxis and food allergy, immunotherapy, immune modulators and biologics, immune deficiency and autoimmunity, T cell and B cell functions, regulatory T cells, natural killer cells, mast cell and eosinophil functions, complement abnormalities.
From the journal's Aims & Scope
Research area (LetPub): ALLERGY-IMMUNOLOGY
Editor-in-chief Harold KimPublisher website
Editorial board by country: none in mainland China; most named Canada 20, United States 4, Japan 2 (26 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Asthma and respiratory diseasesMedicine18%
- Allergic Rhinitis and SensitizationMedicine13%
- Food Allergy and Anaphylaxis ResearchMedicine12.7%
- Drug-Induced Adverse ReactionsMedicine5.3%
- Dermatology and Skin DiseasesMedicine5.1%
- Contact Dermatitis and AllergiesMedicine4.2%
- Urticaria and Related ConditionsMedicine4%
- Coagulation, Bradykinin, Polyphosphates, and AngioedemaMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Allergy | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Allergy | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Allergy | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.96LetPub ·
- Impact factor (publisher) 2025
- 3Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.9Publisher website ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.74LetPub ·
- SNIP 2026-06
- 0.88LetPub ·
- h-index
- 26LetPub ·
- h-index
- 76OpenAlex ·
- i10-index
- 701OpenAlex ·
- 2-year mean citedness
- 3.22OpenAlex ·
- Self-citation rate
- 3.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 54LetPub ·
- Downloads per year (publisher) 2025
- 1,500,000Publisher website ·
Articles by year OpenAlex count · 1,660 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 60 | 60 | 16 |
| 2025 | 66 | 66 | 169 |
| 2024 | 76 | 76 | 465 |
| 2023 | 107 | 107 | 933 |
| 2022 | 113 | 113 | 1,228 |
| 2021 | 136 | 136 | 2,031 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
119 daysMedian, submission to acceptance · P25–P75 78 days – 179 days
- Acceptance to online
- median 24 days (93 articles)
- Submission to online
- median 154 days
- Sample
- 92 articles with submission and acceptance dates (152 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to first decision
- 8 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,690 / USD 3,190 / GBP 2,390 | Yes | CC BY, CC0 | |
| OpenAlex | USD 3,090 / EUR 2,590 / GBP 2,290 | — | — | |
| LetPub | GBP 2,090 / USD 2,890 / EUR 2,390 | Yes | — | |
| Publisher website | GBP 2,390 / USD 3,190 / EUR 2,690 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteArticle types accepted5
- case reportsResearch Reviews Case reports Letters to the Editor Short reportsLength not stated
- letters to the editorResearch Reviews Case reports Letters to the Editor Short reportsLength not stated
- researchResearch Reviews Case reports Letters to the Editor Short reportsLength not stated
- reviewsResearch Reviews Case reports Letters to the Editor Short reportsLength not stated
- short reportsResearch Reviews Case reports Letters to the Editor Short reportsLength not stated
Policy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
CC0 data policy Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
CC BY (Creative Commons Attribution 4.0 International licence) Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Allergy, Asthma & Clinical Immunology articles are published open access under a CC BY (Creative Commons Att…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2005
- ISSN
- 1710-1484
- Electronic ISSN
- 1710-1492
- Society / sponsor
- Canadian Society of Allergy and Clinical Immunology
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Allergy Asthma and Clinical Immunology
What CAS zone is Allergy Asthma and Clinical Immunology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Allergy Asthma and Clinical Immunology is in Zone 4 of Medicine, and in Zone 4 of the minor category Allergy / Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Allergy Asthma and Clinical Immunology?
The latest impact factor listed by LetPub is 2.96; CiteScore 4.9, h-index 76.
How long does peer review take at Allergy Asthma and Clinical Immunology?
Based on the dates recorded on 92 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 119 days (interquartile range 78–179 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Allergy Asthma and Clinical Immunology based?
Of the 26 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Canada (20), United States (4) and Japan (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Allergy Asthma and Clinical Immunology?
According to LetPub and DOAJ records, Allergy Asthma and Clinical Immunology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase and CAS; that list has not been checked against each database.
Is Allergy Asthma and Clinical Immunology open access, and what is the APC?
Allergy Asthma and Clinical Immunology is a fully open-access journal. APC about USD 3,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-30). Last updated: .